P53 EXPRESSION IN PATIENTS WITH MYELODYSPLASTIC SYNDROME AT DIAGNOSIS AND FOLLOWING TREATMENT WITH AZACITIDINE

被引：0
|
作者：
Maung, S. [1 ]
Strahan, N. [1 ]
Desmond, R. [1 ]
McHugh, J. [1 ]
Burke, C. [1 ]
O'Loughlin, J. [2 ]
Jeffers, M. [2 ]
Enright, H. [1 ]
机构：
[1] Tallaght Hosp, Trinity Coll, Sch Med, Haematol, Dublin, Ireland
[2] Tallaght Hosp, Trinity Coll, Sch Med, Cellular Pathol, Dublin, Ireland
来源：
HAEMATOLOGICA | 2015年 / 100卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
E1225
引用
收藏
页码：491 / 491
页数：1
相关论文
共 50 条
  • [1] Relationship between p53 expression and prognosis of myelodysplastic syndrome treated with azacitidine
    Oka, Satoko
    Ono, Kazuo
    Nohgawa, Masaharu
    JOURNAL OF HEMATOPATHOLOGY, 2020, 13 (04) : 213 - 219
  • [2] Relationship between p53 expression and prognosis of myelodysplastic syndrome treated with azacitidine
    Satoko Oka
    Kazuo Ono
    Masaharu Nohgawa
    Journal of Hematopathology, 2020, 13 : 213 - 219
  • [3] Selinexor synergizes with azacitidine to eliminate myelodysplastic syndrome cells through p53 nuclear accumulation
    Guo, Yixuan
    Liu, Zhaoyun
    Duan, Lixiang
    Shen, Hongli
    Ding, Kai
    Fu, Rong
    INVESTIGATIONAL NEW DRUGS, 2022, 40 (04) : 738 - 746
  • [4] Selinexor synergizes with azacitidine to eliminate myelodysplastic syndrome cells through p53 nuclear accumulation
    Yixuan Guo
    Zhaoyun Liu
    Lixiang Duan
    Hongli Shen
    Kai Ding
    Rong Fu
    Investigational New Drugs, 2022, 40 : 738 - 746
  • [5] Evaluation of P53 protein expression in patients with Myelodysplastic Syndrome (MDS): Prognostic impact
    Cascardi, E.
    Napoli, A.
    Ingravallo, G.
    Specchia, G.
    Maiorano, E.
    Resta, L.
    VIRCHOWS ARCHIV, 2016, 469 : S111 - S112
  • [6] Unfavorable outcome of patients with myelodysplastic syndrome IPSS intermediate-1: Relationship to elevated expression of p53 at diagnosis
    Duarte, F.
    Filho, F.
    Barbosa, M.
    Santos, T.
    Goncalves, R.
    LEUKEMIA RESEARCH, 2013, 37 : S101 - S101
  • [7] p53 dysregulation in myelodysplastic syndrome.
    Totzke, G
    Sachinidis, A
    Vetter, H
    Ko, Y
    BLOOD, 1998, 92 (10) : 190B - 190B
  • [8] Azacitidine for the treatment of myelodysplastic syndrome
    Cataldo, Vince D.
    Cortes, Jorge
    Quintas-Cardama, Alfonso
    EXPERT REVIEW OF ANTICANCER THERAPY, 2009, 9 (07) : 875 - 884
  • [9] Characterization of p53 and MYC Expression in Acute Myeloid Leukemia and Myelodysplastic Syndrome
    Gao, Linlin
    Saeed, Azhar
    Golem, Shivani
    Zhang, Da
    Woodroof, Janet
    Cui, Wei
    MODERN PATHOLOGY, 2020, 33 (SUPPL 2) : 1298 - 1298
  • [10] Characterization of p53 and MYC Expression in Acute Myeloid Leukemia and Myelodysplastic Syndrome
    Gao, Linlin
    Saeed, Azhar
    Golem, Shivani
    Zhang, Da
    Woodroof, Janet
    Cui, Wei
    LABORATORY INVESTIGATION, 2020, 100 (SUPPL 1) : 1298 - 1298
12345